BIO.B: Bio-Rad Laboratories, Inc. Stock

by  •  • Comments Off on BIO.B: Bio-Rad Laboratories, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 0.00
Enterprise Value ($M) 763.97
Book Value ($M) 9,615.25
Book Value / Share 324.89
Price / Book 0.00
NCAV ($M) -728.44
NCAV / Share -24.61
Price / NCAV 0.00

Profitability (mra)
Return on Invested Capital (ROIC) -0.30
Return on Assets (ROA) -0.20
Return on Equity (ROE) -0.27

Liquidity (mrq)
Quick Ratio 4.29
Current Ratio 5.55

Balance Sheet (mrq) ($M)
Current Assets 3,157.98
Assets 13,501.67
Liabilities 3,886.41
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 2,802.25
Operating Income 499.05
Net Income -3,627.53
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 194.45
Cash from Investing -1,207.59
Cash from Financing 973.58

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-11 13D/A Schwartz Alice N 89.70

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2023-02-17 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT T
2022-10-28 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO
2022-07-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU
2022-04-29 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P

(click for more detail)

Similar Companies
AME – AMETEK, Inc. AVTR – Avantor Inc
BIO – Bio-Rad Laboratories, Inc. BMI – Badger Meter, Inc.
DHR – Danaher Corporation


Financial data and stock pages provided by
Fintel.io